• Journal of Yeungnam Medical Science
• /
• 제27권1호
• /
• pp.18-26
• /
• 2010

The clinical picture in severe cases of pandemic (H1N1) 2009 influenza is markedly different from the disease pattern seen during the epidemics of seasonal influenza as many of those affected were previously healthy young people. Current predictions estimate that during a pandemic wave, 12~30% of the population will develop clinical influenza (compared with 5~15% for seasonal influenza) with 4% of those patients requiring hospital admissions and one in five requiring critical care. Until July 6, 94,512 people have been infected in 122 countries, of whom 429 have died with an overall case-fatality rate of <0.5%. Most of the confirmed cases of S-OIV (Swine-Origin Influenza A Virus) infection have been characterized by a self-limited, uncomplicated febrile respiratory illness and 38% of the cases have also included vomiting or diarrhea. Efforts to control these outbreaks are based on our understanding of novel S-OIV (Swine-Origin Influenza A Virus) and the previous influenza pandemics. So, this review covers the experience with S-OIV (Swine-Origin Influenza A Virus) for the admission and background data and the clinical presentation, diagnosis and treatment of H1N1 in pediatric patient with S-OIV (Swine-Origin Influenza A Virus) at YUMC, 2009.

• Journal of Ginseng Research
• /
• 제35권1호
• /
• pp.104-110
• /
• 2011

Korean red ginseng (RG), which is a ginseng treated by heating and steaming, has biological activity similar to Panax ginseng. The effect of ginseng on influenza infection has not been studied although it is known to have a broad range of biological activities. The aim of the study is to investigate the effect of RG extract on influenza A (H1N1) virus infection. We investigated the inhibitory effect of RG extract on plaque formation by influenza A virus in a cell-based plaque assay, and the effect of orally administered RG on influenza A virus infection in mice. RG extract, which was applied at a non-cytotoxic concentration, inhibited plaque formation by influenza A virus in the cell-based plaque assay. The orally administered RG extract ameliorated body weight loss and significantly increased survival in mice infected with influenza A virus. Our results suggest that RG extract has components that reduce the severity of infection by influenza A virus and could potentially be used as a complement to treatment of influenza A virus infections.

• Journal of Microbiology and Biotechnology
• /
• 제29권8호
• /
• pp.1184-1192
• /
• 2019

The influenza A virus is a highly infectious respiratory pathogen that sickens many people with respiratory disease annually. To prevent outbreaks of this viral infection, an understanding of the characteristics of virus-host interaction and development of an anti-viral agent is urgently needed. The influenza A virus can infect mammalian species including humans, pigs, horses and seals. Furthermore, this virus can switch hosts and form a novel lineage. This so-called zoonotic infection provides an opportunity for virus adaptation to the new host and leads to pandemics. Most influenza A viruses express proteins that antagonize the antiviral defense of the host cell. The non-structural protein 1 (NS1) of the influenza A virus is the most important viral regulatory factor controlling cellular processes to modulate host cell gene expression and double-stranded RNA (dsRNA)-mediated antiviral response. This review focuses on the influenza A virus NS1 protein and outlines current issues including the life cycle of the influenza A virus, structural characterization of the influenza A virus NS1, interaction between NS1 and host immune response factor, and design of inhibitors resistant to the influenza A virus.

• 보건교육건강증진학회지
• /
• 제19권2호
• /
• pp.127-138
• /
• 2002

Objective: This prospective survey assessed factors associated with influenza vaccination behaviors among high-risk adults. Methods: 106 patients aged 65 or high risk for complications of influenza were interviewed to identify influencing factors to vaccination. Six potential consequences of Influenza infection and nine factors of vaccination were analysed between compliance and non-compliance groups. Results: Among the 106 patients, the vaccination rate was 62.3%. The rate of the group under the sixties was 37.0010, but the rate over the sixties was 88.5%. Factors in dependently associated with both influenza vaccination behaviors included older age, chronic disease, and especially, related to factors in older age were having positive attitudes toward immunization, perceived severity of infection and willingness to comply with the provider's recommendation. Conclusions: Emphasis on provider recommendations and the knowledge and attitudes of influenza infection and vaccination may enhance influenza vaccination rates in the organized vaccination programs.

• Natural Product Sciences
• /
• 제29권2호
• /
• pp.113-119
• /
• 2023

Descurainia sophia seeds methanol extract showed significant anti-influenza activity and we tried to isolate anti-influenza compounds from the D. sophia extract. D. sophia seeds were extracted with 80% methanol and fractionated with n-hexane, ethyl acetate, CHCl₃ and n-butanol. The anti-influenza activity of each fraction was assessed using sulforhodamine B (SRB) method in A549 cells, human-derived lung cancer cells. The ethyl acetate and CHCl₃ fractions showed the most potent anti-influenza activity. Seven compounds were isolated from CHCl₃ fraction and identified 1-decanol (1), 2-(3,4-dihydroxy-2-methylenebutoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (2), daucosterol (3), isorhamnetin (4), quercetin (5), sinapic acid (6), and helveticoside (7) by spectroscopic data such as UV, IR, ¹H-NMR, ¹³C-NMR and mass spectroscopy. Anti-influenza activities of isolated compounds were evaluated using SRB method in A549 cells. Compounds 3, 4 and 7 had significant anti-influenza activity in a dose-dependent manner.

• Pediatric Infection and Vaccine
• /
• 제27권1호
• /
• pp.53-61
• /
• 2020

목적: 부모의 소아 자녀에 대한 인플루엔자 및 인플루엔자 백신 관련한 인식도 차이 및 변화를 홍보물 교육 유무에 따라 비교 분석하였다. 방법: 2015년 서울, 경기 북부 5개 지역 거주자 중 생후 6개월부터 59개월까지의 자녀가 있는 보호자 1,034명을 대상으로, 설문지 조사를 시행하였다. 설문내용은 인플루엔자 및 인플루엔자 백신에 대한 인식 및 변화 및 인플루엔자 예방접종 의향 및 이유 등을 포함하였다. 부모는 3군으로 나누어 교육 유무(A군: 교육받지 않음, B군: 교육받음)에 따른 인식도 차이와 교육 전후(C군)의 인식도 변화를 분석하였다. 결과: A군과 B군 간 교육에 따른 인식도 차이 중 의미 있는 항목은 '자녀가 고위험군임을 인식함', '독감 예방접종은 효과적', '독감 예방접종은 비쌈' 등이었다. C군에서 교육 전후에 따른 인식도 변화 중 의미 있는 항목은 '자녀가 고위험군임을 인식함', '독감 예방접종은 안전함', '독감 예방접종은 비쌈', '독감 예방접종을 부정적으로 인식함' 등이었다. 결론: 인플루엔자와 인플루엔자 예방접종에 대한 부모의 인식은 홍보물 교육 이후 긍정적인 효과를 보였다.

• Pediatric Infection and Vaccine
• /
• 제27권3호
• /
• pp.171-179
• /
• 2020

목적: 제주 지역에서 2017-2018 절기와 2018-2019 절기에 소아 연령에서 인플루엔자의 역학에 대해 알아보고자 하였다. 이에 더하여 국내 인플루엔자 표본감시체계와 비교하여 그 대표성을 확인해보고자 하였다. 방법: 2017-2018, 2018-2019 각각의 절기에 제주대학교 병원에 방문하여 인플루엔자 검사를 시행 받은 13세 미만의 소아를 대상으로 하였다. 의무기록을 통하여 대상 환자들의 인구학적 자료, 인플루엔자 검사 결과를 후향적으로 분석하였다. 결과: 총 5,219명의 인플루엔자 의사환자가 연구 대상자로 포함되었다. 전체적으로 연구 대상자의 평균 나이는 2.85±2.79세 였고, 두 절기 모두 인플루엔자 의사환자는 1세 연령 그룹이 가장 많았다. 인플루엔자 감염이 확인된 소아는 총 902 (17.3%) 명이었다. 2017-2018 절기에는인플루엔자 A형의양성률은 10.4% (236/2,279), 인플루엔자 B형의양성률은 9.1% (208/2,279) 이었다. 2018-2019 절기에는 인플루엔자 A형의 양성률은 10.3% (303/2,940), 인플루엔자 B형의 양성률은 5.3% (155/2,940) 이었다. 인플루엔자 환자의 평균 연령은 2017-2018 절기에는 4.09세, 2018-2019 절기에는 5.05세로 통계적으로 유의한 차이를 보였다 (P<0.05). 인플루엔자의 주별 분포는 국내 임상감시시스템의 인플루엔자 의사환자와 유사한 형태로 나타났다.결론: 제주 지역에서 2017-2018 절기와 2018-2019 절기 사이에 인플루엔자 유행 양상과 연령 분포의 뚜렷한 차이를 보였다.국내 다른 지역과의 역학적 특성과 비교하여 제주 지역 고유의 인플루엔자 역학에 대한 지속적인 연구가 필요하다.

• Tuberculosis and Respiratory Diseases
• /
• 제80권4호
• /
• pp.392-400
• /
• 2017

Background: Most patients with influenza recover spontaneously or following treatment with an anti-viral agent, but some patients experience pneumonia requiring hospitalization. We conducted a retrospective review to determine the incidence and risk factors of pneumonia in hospitalized patients with influenza A or B. Methods: A total of 213 patients aged 18 years or older and hospitalized with influenza between January 2012 and January 2015 were included in this study. A reverse-transcriptase polymerase chain reaction assay was used to detect the influenza A or B virus in the patients' sputum samples. We collected demographic and laboratory data, combined coexisting diseases, and radiologic findings. Results: The incidence of pneumonia was higher in patients in the influenza A group compared to those in the influenza B group (68.6% vs. 56.9%), but this difference was not statistically significant. The presence of underlying respiratory disease was significantly associated with pneumonia in the influenza A group (adjusted odds ratio [OR], 3.975; 95% confidence interval [CI], 1.312-12.043; p=0.015). In the influenza B group, the white blood cell count (adjusted OR, 1.413; 95% CI, 1.053-1.896; p=0.021), platelet count (adjusted OR, 0.988; 95% CI, 0.978-0.999; p=0.027), and existence of an underlying medical disease (adjusted OR, 15.858; 95% CI, 1.757-143.088; p=0.014) were all significantly associated with pneumonia in multivariate analyses. Conclusion: The incidence of pneumonia was 65.7% in hospitalized patients with influenza A or B. The risk factors of pneumonia differed in hospitalized patients with influenza A or B.

• Clinical and Experimental Pediatrics
• /
• 제56권4호
• /
• pp.165-175
• /
• 2013

Purpose: There was a global increase in the prevalence of oseltamivir-resistant influenza viruses during the 2007-2008 influenza season. This study was conducted to investigate the occurrence and characteristics of oseltamivir-resistant influenza viruses during the 2007-2008 and 2008-2009 influenza seasons among patients who were treated with oseltamivir (group A) and those that did not receive oseltamivir (group B). Methods: A prospective study was conducted on 321 pediatric patients who were hospitalized because of influenza during the 2007-2008 and 2008-2009 influenza seasons. Drug resistance tests were conducted on influenza viruses isolated from 91 patients. Results: There was no significant difference between the clinical characteristics of groups A and B during both seasons. Influenza A/H1N1, isolated from both groups A and B during the 2007-2008 and 2008-2009 periods, was not resistant to zanamivir. However, phenotypic analysis of the virus revealed a high oseltamivir $IC_{50}$ range and that H275Y substitution of the neuraminidase (NA) gene and partial variation of the hemagglutinin (HA) gene did not affect its antigenicity to the HA vaccine even though group A had a shorter hospitalization duration and fewer lower respiratory tract complications than group B. In addition, there was no significant difference in the clinical manifestations between oseltamivir-susceptible and oseltamivir-resistant strains of influenza A/H1N1. Conclusion: Establishment of guidelines to efficiently treat influenza with oseltamivir, a commonly used drug for treating influenza in Korean pediatric patients, and a treatment strategy with a new therapeutic agent is required.

• Journal of Preventive Medicine and Public Health
• /
• 제38권4호
• /
• pp.386-390
• /
• 2005

Influenza A viruses periodicall y cause worldwide epidemics, or pandemics, with high rates of illness and death. A pandemic can occur at any time, with the potential to cause serious illness, death and social and economic disruption throughout the world. Historic evidence suggests that pandemics occurred three to four times per century. In the last century there were three influenza pandemics. The circumstances still exist for a new influenza virus with pandemic potential to emerge an d spread. The unpredictability of the timing of the next pandemic is underlined by the occurrence of several large outbreaks of highly pathogenic avian influenza since the early 1980s. In 1999, the World Health Organization published the Influenza pandemic plan. The role of WHO and guidelines for national and regional planning. And in 2005, WHO revised the global influenza preparedness plan for new national measures before and during pandemics. This document outlines briefly the Korean Centers for Disease Control's plan for responding to an influenza pandemic. According to the new pandemic phases of WHO, we set up the 4 national levels of preparedness and made guidelines for preventing and control the epidemics in each phase. And also we described the future plans to antiviral stockpiles and pandemic vaccine development.